Xenetic Biosciences Statistics
Total Valuation
XBIO has a market cap or net worth of $4.55 million. The enterprise value is -$477,278.
Important Dates
The next confirmed earnings date is Wednesday, August 13, 2025, before market open.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
XBIO has 1.54 million shares outstanding. The number of shares has increased by 0.25% in one year.
| Current Share Class | 1.54M |
| Shares Outstanding | 1.54M |
| Shares Change (YoY) | +0.25% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 6.89% |
| Owned by Institutions (%) | 7.88% |
| Float | 1.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.76 |
| Forward PS | 1.98 |
| PB Ratio | 0.97 |
| P/TBV Ratio | 0.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.93
| Current Ratio | 5.93 |
| Quick Ratio | 5.29 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -51.83% and return on invested capital (ROIC) is -34.31%.
| Return on Equity (ROE) | -51.83% |
| Return on Assets (ROA) | -28.37% |
| Return on Invested Capital (ROIC) | -34.31% |
| Return on Capital Employed (ROCE) | -73.38% |
| Revenue Per Employee | $1.22M |
| Profits Per Employee | -$1.54M |
| Employee Count | 2 |
| Asset Turnover | 0.34 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -9.48% in the last 52 weeks. The beta is 2.33, so XBIO's price volatility has been higher than the market average.
| Beta (5Y) | 2.33 |
| 52-Week Price Change | -9.48% |
| 50-Day Moving Average | 3.36 |
| 200-Day Moving Average | 3.56 |
| Relative Strength Index (RSI) | 39.90 |
| Average Volume (20 Days) | 47,721 |
Short Selling Information
The latest short interest is 43,583, so 2.83% of the outstanding shares have been sold short.
| Short Interest | 43,583 |
| Short Previous Month | 32,752 |
| Short % of Shares Out | 2.83% |
| Short % of Float | 3.68% |
| Short Ratio (days to cover) | 0.77 |
Income Statement
In the last 12 months, XBIO had revenue of $2.45 million and -$3.08 million in losses. Loss per share was -$2.00.
| Revenue | 2.45M |
| Gross Profit | 2.45M |
| Operating Income | -3.27M |
| Pretax Income | -4.47M |
| Net Income | -3.08M |
| EBITDA | n/a |
| EBIT | -3.27M |
| Loss Per Share | -$2.00 |
Full Income StatementBalance Sheet
The company has $4.78 million in cash and n/a in debt, giving a net cash position of $4.78 million or $3.10 per share.
| Cash & Cash Equivalents | 4.78M |
| Total Debt | n/a |
| Net Cash | 4.78M |
| Net Cash Per Share | $3.10 |
| Equity (Book Value) | 4.45M |
| Book Value Per Share | 2.88 |
| Working Capital | 4.45M |
Full Balance SheetCash Flow
| Operating Cash Flow | -2.52M |
| Capital Expenditures | n/a |
| Free Cash Flow | -2.52M |
| FCF Per Share | -$1.63 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -133.49% and -126.03%.
| Gross Margin | 100.00% |
| Operating Margin | -133.49% |
| Pretax Margin | -126.03% |
| Profit Margin | -126.03% |
| EBITDA Margin | n/a |
| EBIT Margin | -133.49% |
| FCF Margin | n/a |